Dainippon’s Latuda gets approval in Canada to treat bipolar depression
Latuda, the antipsychotic agent, has been marketed for the treatment of schizophrenia in Canada by Sunovion Pharmaceuticals Canada, a subsidiary of the US-based Sunovion Pharmaceuticals. The company said
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.